Facebook-f Twitter Tiktok Instagram Youtube
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

21.76

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

-0.03

EPS Last/This Y

-9.79

EPS This/Next Y

1.2

Price

5.39

Target Price

30.5

Analyst Recom

1

Performance Q

5.98

Relative Volume

2.2

Beta

1.46

Ticker: DTIL



20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-05-09DTIL5.19N/AN/A0
2025-05-12DTIL5.23N/AN/A0
2025-05-13DTIL5.17N/AN/A0
2025-05-14DTIL4.96N/AN/A0
2025-05-15DTIL4.55N/AN/A0
2025-05-16DTIL4.65N/AN/A0
2025-05-19DTIL4.67N/AN/A0
2025-05-20DTIL4.87N/AN/A0
2025-05-21DTIL4.58N/AN/A0
2025-05-22DTIL4.6N/AN/A0
2025-05-23DTIL4.55N/AN/A0
2025-05-27DTIL4.92N/AN/A0
2025-05-28DTIL4.94N/AN/A0
2025-05-29DTIL4.92N/AN/A0
2025-05-30DTIL4.82N/AN/A0
2025-06-02DTIL5.04N/AN/A0
2025-06-03DTIL5.1N/AN/A0
2025-06-04DTIL5.15N/AN/A0
2025-06-05DTIL5.19N/AN/A0
2025-06-06DTIL5.27N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1



20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-05-09DTIL5.13- - -10.22
2025-05-12DTIL5.22- - -10.22
2025-05-13DTIL5.14- - -10.22
2025-05-14DTIL4.97- - -10.22
2025-05-15DTIL4.55- - -10.22
2025-05-16DTIL4.65- - -10.22
2025-05-19DTIL4.69- - -8.54
2025-05-20DTIL4.81-154.6- -8.54
2025-05-21DTIL4.60-154.6- -8.54
2025-05-22DTIL4.62-154.6- -8.54
2025-05-23DTIL4.59-154.6- -8.54
2025-05-27DTIL4.89-147.2- -8.74
2025-05-28DTIL5.00-147.2- -8.74
2025-05-29DTIL4.96-147.2- -8.74
2025-05-30DTIL4.83-147.2- -8.74
2025-06-02DTIL5.03-147.2- -8.74
2025-06-03DTIL5.15-147.2- -8.74
2025-06-04DTIL5.16-147.2- -8.74
2025-06-05DTIL5.13-147.2- -8.74
2025-06-06DTIL5.39-147.2- -8.74
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1



20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-05-09DTIL-1.1122.7721.96
2025-05-12DTIL-2.8419.9022.45
2025-05-13DTIL-2.8419.9022.45
2025-05-14DTIL-1.1119.9022.45
2025-05-15DTIL-1.1119.9022.45
2025-05-16DTIL-1.1119.9022.45
2025-05-19DTIL-1.069.6422.45
2025-05-20DTIL-1.069.6422.45
2025-05-21DTIL-1.069.6422.45
2025-05-22DTIL-1.169.6422.45
2025-05-23DTIL-1.169.6422.45
2025-05-27DTIL-1.1611.6722.45
2025-05-28DTIL-1.1611.6721.76
2025-05-29DTIL-1.1611.6721.76
2025-05-30DTIL-1.1611.6721.76
2025-06-02DTIL-1.1611.6721.76
2025-06-03DTIL-1.1611.6721.76
2025-06-04DTIL-1.1611.6721.76
2025-06-05DTIL-1.1611.6721.76
2025-06-06DTIL-1.1611.6721.76
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

-2.21

Avg. EPS Est. Current Quarter

-2.21

Avg. EPS Est. Next Quarter

-2.24

Insider Transactions

-1.16

Institutional Transactions

11.67

Beta

1.46

Average Sales Estimate Current Quarter

6

Average Sales Estimate Next Quarter

5

Fair Value

Quality Score

28

Growth Score

40

Sentiment Score

23

Actual DrawDown %

98.9

Max Drawdown 5-Year %

-99.2

Target Price

30.5

P/E

Forward P/E

PEG

P/S

1.19

P/B

1.17

P/Free Cash Flow

EPS

-2.01

Average EPS Est. Cur. Y​

-8.74

EPS Next Y. (Est.)

-7.55

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-42.99

Relative Volume

2.2

Return on Equity vs Sector %

-68.6

Return on Equity vs Industry %

-50.6

EPS 1 7Days Diff

1.5

EPS 1 30Days Diff

1.48

EBIT Estimation

Precision BioSciences, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 107
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
stock quote shares DTIL – Precision BioSciences, Inc. Stock Price stock today
news today DTIL – Precision BioSciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch DTIL – Precision BioSciences, Inc. yahoo finance google finance
stock history DTIL – Precision BioSciences, Inc. invest stock market
stock prices DTIL premarket after hours
ticker DTIL fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Facebook-f Twitter Tiktok Instagram Youtube

Get Started

About